After 56 weeks: Placebo group lost 1.6% of body weight Starting dose (3.75/23 mg) group lost 5.1% of body weight Top dose (15/92 mg) group lost 10.9% of body weight Beyond weight loss, the CONQUER trial showed significant improvements in blood pressure, waist circumference, lipid profiles, glycemic parameters, and inflammatory biomarkers compared to placebo
Habener was honored alongside Rockefeller University researcher Svetlana Mojsov and Novo Nordisk scientist Lotte Bjerre Knudsen for their discovery and development of GLP-1 pharmaceuticals, which have revolutionized treatments for obesity and type 2 diabetes, including the creation and FDA approval of Ozempic and Wegovy
Initially developed for type 2 diabetes, these drugs are now widely used for obesity and cardiovascular risk reduction, with emerging applications in neurological disease [2, 3]
Numbness & Tingling: Some users experience carpal tunnel-like symptoms due to fluid retention affecting nerve pathways
Mitochondrial-Derived Peptides: Mechanisms and Applications
